학술논문
'학술논문'
에서 검색결과 2건 | 목록
1~10
Conference
Liang, X.; Hodsdon, A.; Chapman, R.; Burns, M.; Keyes, K.; Ollier, J.; Papenberg, A.; Spohr, K.; Azaiez, F.; Ibrahim, F.; Stanoiu, M.; Haas, F.; Caurier, E.; Curien, D.; Nowacki, F.; Salsac, M.-D.; Bazzacco, D.; Beghini, S.; Farnea, E.; Menegazzo, R.; Montagnoli, G.; Scarlassara, F.; Behera, B.R.; Berti, L.; Corradi, L.; De Angelis, G.; Fioretto, E.; Gadea, A.; Latina, A.; Margineau, N.; Napoli, D.R.; Stefanini, A.M.; Szilner, S.; Toniolo, N.; Trotta, M.; Wang, Z.; Deacon, A.; Smith, J.F.; Dombradi, Zs.; Jungclaus, A.; Pollarolo, G.; Pucknell, V.F.E.; Verney, D.; Wrzesinski, J.
In: AIP Conference Proceedings , Fusion06: Reaction Mechanisms and Nuclear Structure at the Coulomb Barrier. (AIP Conference Proceedings, 2006, 853:37-42)
Report
Sverman , Restrepo L, Mathews GC. Poststroke seures. Arch Neurol. 2002 Feb;59(2):195-201. do 10.1001/archneur.59.2.195.
Stephen LJ, Brod MJ. Epepsy elderly people. Lancet. 2000 Apr 22;355(9213):1441-6. do 10.1016/S0140-6736(00)02149-8.
zarD. The aln Gueles for stroke preventn. The Stroke Preventn and Educatnal Awareness Dfusn (SPREAD) Collaboratn. Neurol Sc 2000 Feb;21(1):5-12. do 10.1007/s100720070112. No abstract avaable.
Hauser WA, Annegers JF, Kurland LT. cence of epepsy and unprovoked seures Rochester, Mnesota: 1935-1984. Epeps. 1993 May-Jun;34(3):453-68. do 10.1111/j.1528-1157.1993.tb02586.x.
Blad CF, Alexandrov AV, Bellavance A, BornsteN , Chambers B, Cote R, Lebrun L, PA, Norr JW. Seures after stroke: a prospecte multenter study. Arch Neurol. 2000 Nov;57(11):1617-22. do 10.1001/archneur.57.11.1617.
Rhoney DH, Tps LB, Murry KR, Basham MC, Mhael DB, Copl WM. Antonvulsant prophylax and tg of seures after aneurysmal subarachno hemorrhage. Neurology. 2000 Jul 25;55(2):258-65. do 10.1212/wnl.55.2.258.
Olafsson E, Gudmundsson G, Hauser WA. Rk of epepsy long-term survors of surgery for aneurysmal subarachno hemorrhage: a populatn-based study eland. Epeps. 2000 Sep;41(9):1201-5. do 10.1111/j.1528-1157.2000.tb00326.x.
Berger AR, Lton RB, Lesser ML, Lantos G, Portenoy RK. Early seures followg tracerebral hemorrhage: platns for therapy. Neurology. 1988 Sep;38(9):1363-5. do 10.1212/wnl.38.9.1363.
Sung CY, Chu NS. Epept seures thrombot stroke. J Neurol. 1990 Jun;237(3):166-70. do 10.1007/BF00314589.
- Bnstl S., Wulfert E., Beck SG., Levetacetam (ucb L059) affects vro model of epepsy CA3 pyramal neurons whout alterg normal synapt transmsn. Naunyn Schmeberg Arch Pharmacol 1997: 356:611-618 - Bchoff U. And Schlobohm - Levetacetam Has No Effect On Voltage-Gated Potassm Currents Cultured Mouse Hpocampal Neurons. Epeps 43(Suppl. 8):88, 2002. - Bla L, Sheehy O, St-Hae JM, Bernr JP, Godfro P, Le Lorr J. Econom evaluatn of levetacetam as adjuncte therapy refractory epept patnts. Value Health 2002;5(6):509 - Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Dose-response effect of levetacetam 1000 and 2000 mg/day partl epepsy. Epepsy Research 2002;48:77-89
- Castlo et al., Cochrane Database Syst Rev 2000;(3):CD 002028 - Chadwk et al., Cochrane Database Syst Rev 2002;(2):CD 001416 - Chaewul et al., Cochrane Database Syst Rev 2001;(1):CD 001901 - Coupez R., Nolas JM, Browne TR Levetacetam, a new antpept agent: lack of vro and vo pharmacoket teractn wh phenyto patnt wh valpro ac. Epeps 2003;44:171-178 - Cramer JA, Arro C, Van Hammee G, Gauer LJ, Cereghno JJ. Effect of levetacetam on epepsy-related qualy of le. Yhe N132 study group. Epeps 2000;41:868-874 - Cramer JA, Van Hammee G, N132 study Group. Matenance of provement health-related qualy of le durg long-term treatment wh levetacetam. Epepsy Behav 2003;4:118-123
- Cramer J, De Rue K, Devsky O, Edrh P, Trble MR. A systemat revw of the behavral effects of levetacetam adults wh epepsy, cogne dorder or an anxty dorder durg clal trl. Epepsy Behav. 2003;4:124-132 - Cramer JA, Ben-Menachem E, Franch J. Revw of treatment optns for refractory epepsy: new medatns and vagal nerve stulatn. Epepsy Research 2001;47:17-25 - Cramer J.A., Lepp E., De Rue K., Eldrh P., Kramer G. - Toleraby of levetacetam elderly patnts wh CNS dorders - Epepsy Research 2003; 56:135-145 - Devsky O, Elger C. Effacy of levetacetam partl seure. Epept Dorder 2003;5(suppl 1):S27-S32
- FerrendellJ.A., French J., Lepp., Morrel M.J., Herbeuval A., Han J., Magnus L. - Use of levetacetam a populatn of patnts aged 65 years and older: a subset analys of the KEEPER trl - Epepsy & Behavr 2003; 4:702-709 - French J, Edrh P, Cramer JA. A systemat revw of safety profe of levetacetam: a new antpept drug. Epepsy Res 2001;47:77-90 - Fucks B, Glard M, Mhel P, Lynch B, Vertongen P, Leprce P, Klgaard H, Chatela P. - Localatn and photoaffy labellg of the levetrcetam ddg se rat bra and certa cell les Eur. J. Pharmacol 2003; 478, 11-19 - Glard M, Fucks B, Mhel P, Vertongen P, Massgham R, Chatela P Bdg characterth of [3H]ucb 30889 to levetacetam bdg ses rat bra Eur J Phamacol 2003; 478: 1-9
- Glno RA, Hrsemenzel R, Baltes E, et al fluence of new antpept drug (levetacetam ucb L057) on the pharmacokets and pharmacodynams of oral contraceptes Epeps 1996; 37 (Suppl.4):90 - Glauser TA, Pellock JM, Beb EM. Effacy and safety of levetacetam chdren wh partl seure: an open label trl. Epeps 2002;43:518-524 - Glauser TA, Dulac O. Prelary effacy of levetacetam chdren. Epept Dorder 2003;5(suppl 1):S45-S50 - Godfro P, Hart Y, Roberts R, Le Lorr J. Seure freedom patnts treated wh adjuncte levetacetam: econom evaluatn wh the NHS. Neurology 2003;60(S1):A433-A434 - Gower AJ, Hsch E, Boehrer A, et al. Effects of levetacetam, a novel antpept drug on convulsant acty two genet rat models of epepsy Epepsy Research 1995; 22: 207-13
- Gower AJ, Noyer M, Verloes R., et al. ucb L059, a novel antconvulsant drug: pharmacologal profle anals. Eur J Pharmacol. 1992; 222: 193-203 - Gu J., Lynch B. A., Anderson D., Klgaard H., Lu s., Elashoff M., Ebert U., Potschka H. - Loscher W. - The antpept drug levetacetam selectely mods kdlg-duced alteratns gene expressn the temporal lobe of rats. - European Journal of Neuroscnce Vol. 19, pp334-345, 2004 - Kastela-Nolst Trenè DGA, Hsch E. Levetacetam: prelary effacy generaled seure. Epept Dorder 2003;5(suppl 1):S39-S44 - Klgaard H, Matagne A, Gobert M, Mhel P Evence for a unue profe of levetacetam rodent models of seures and epepsy Eur. J. Pharmacology 1998; 353: 191-206
- Klgaard H, Pkanen A, Antpeptogenes, neuroprotectn, and dease modatn the treatment of epepsy: focus on levetacetam. Epept dorder 2003; 5:S9-S16 - Kraemer G, Eldrh P. Levetacetam Elderly patnts wh epepsy - The Ameran Eplepsy Socty and The Ameran Clal Neurophyslogy Socty - Jot Meetg November 30-December 5, 2001 - Krakow K, Walker M, Otoul C, Sander JWAS. Long-term contuatn of Levetacetam patnts wh refractory epepsy. Neurology 2001;56:1772-1774 - Krauss GL, Abou-khal B, Sheth SG. Effacy of levetacetam for treatment fo drug-restant generaled epepsy. Epeps 2001;42(suppl 7):181 - Krauss GL, Betts T, Abou-Khal B, Bergey G, Yarrow H, Mler A. Levetacetam treatment of path generaled epepsy. Seure 2003;12:617-620
- Lagae L, Buyse G, Deconck A, Ceulemans B. Effect of levetacetam refractory chdhood epepsy syndromes. Eur J Paedtr Neurol 2003;7:123-128 - Levy RH, Raguenau-Majless Baltes E Repeated admtratn of the novel antpept agent levetacetam does not alter dox pharmacokets and pharmacodynams healthy volunteers Epepsy Research 2001; 47: 55-63 - Loscher W, Honak D, Rundfeld C Antpeptogen effect of the novel antonvulsant levetacetam (ucb L059) the kdlg model of temporal lobe epepsy. - J. Pharmacologal Exp. Ther 1998; 284: 474-9 - Lukyanetz EA, Shkryl VM, Kostyuk PG Selecte blockade ofN -type Calcm Channels by levetacetam Epeps 2002; 43(1): 9-18 - Madeja M., Margeanu D.G., GorjA., Sp E., Boerrter P., Klgaard H., Et Al.
- Madeja M., Margeanu D.G., GorjA., Sp E., Boerrter P., Klgaard H., Et Al. Reductn Of Voltage-Operated Potassm Currents By Levetacetam: A Novel Antpept Mechanm Of Actn? - Neuropharmacology Oct-2003. 45(5):661-671. - Margeau D. G., Klgaard Henr Levetacetam - Mechanm of actn - Antpect drugs, 5th edn. Eded by R.H. Levy, R.H. Mattson, B.S. Meldrum, and E.Perucca. Phadelph: Lpcott Wlms & Wks, 2002 - Margeau DG, Klgaard H hn of neural hyperynchrony vro dferenttes levetacetam fro classal antpept drugs Pharmacol. Research 2000; 42(4): 281-285 - Marson AG, Hutton JL, Leach JP. Levetacetam, Oxcarbazepe, Remaceme and zoname for drug restant localatn-related epepsy: a systemat revw. Epepsy Res 2001;46:259-270
- Marson AG, Kad ZA, Hutton JL, Chadwk DW. The new antpept drugs: a systemat revw of the effacy and toleraby. Epeps 1997;38:859-880 - Morrell MJ, Lepp French J, FerrendellJ, Han J, Magnus L. The KEEPER trl: levetacetam adjuncte treatment of partl-onset seure an open-label communy-based study. Epepsy Res 2003;54:153-161 - Nspodzny Klgaard H, Margeau DG Desynchrong effect of levetacetam on epeptorm responses rat hpocampal sles Neuropharmaology Neuroreport 2003; vol14(9): 1273-1276 - Noyer M, Glard M, Magagne A., et al. The novel antpept drug levetacetam (ucb L059) appears o act v a spec bdg se CNS membranes. Eur J Pharmacol 1995 ; 286 : 137-146 - Patsalos PN Pharmacoket profe of levetacetam: toward eal characterts. Pharmacol. Ther 2000; 83: 77-85 - Patsalos PN The pharmacoket characterts of levetacetam. Method Fd. Exp. Cl Pharmacol. 2003; 25: 123-129
- Perucca E, Johannessen SThe eal pharmacoket properts of an antpept drug: how close does levetacetam come? Epept Dorder 2003; 5(suppl 1):S17-S26 - Perucca E. Pharmacokets. :Engel J Jr, Pedley TA Epepsy-A comprehense Textbook. New York: Raven Press 1997:1131-1153 - Radtke RA Pharmacokets of levetacetam Epeps 2001; 42(Suppl 4):24-7 - Raguenau-Majless Levy RH, Meyerhoff C Lack of effect of repeated admtratn of levetacetam on the pharmacodynams and pharmaket profe of warfar Epepsy Res 2001; 47: 55-63 - Ro JM, Hans G, Nguyen L, et al. The antpept drug levetacetam reverses the hn by negate alloster modulators of neuronal GABA - and Glyce-gated current. Br J Pharmacol 2002; 136:659-72 - Sadek AH, F A, French J. Levetacetam related behavural adverse events: a post-marketg study. Epeps, 2002;43S8:151
- Shorvon SD, Van Rckevorsel. A new antpept drug Levetacetam, a pyrrolone recently lensed as an antpept drug. J Neurol Neurosurg Psychtry 2002 ;72: 426-429 - Smh K, Betts T, Prchett L. Levetacetam, a promg optn for the treatment of juvene myoclon epepsy. Epeps 2000;41(suppl1):39 - Van Rckevorsel K. The " number needed to treat " wh levetacetam : comparon wh the other new antpept drugs. Seure 2001;10:235-236 - Welty TE, Gal BE, Fker DM, Prera MD. Levetacetam: a dferent approach to the pharmacotherapy of epepsy. The Annals of Pharmacotherapy 2002;36:296-304 - Zona C, Nspodzny MarchettC, et al. Levetacetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seure 2001; 10: 279-86
- Groletto Francesco, Zappalà Gseppe, Anderson Dallas W., Lebowz Barry D. Norms for the M-Mental State Examatn a Healthy populatn. Neurology 1999;53:315-320 - Measso G., Zappalà G., Cavarzeran F, Crook TH, RomanL, Pozzolo FJ, Groletto F., AmaduccLA, Lebowz BD. Raven's colored progresse matres: a normate study of a random sample of healthy adults. Acta Neurol. Scandava 1993:88:70-74 - Spnler Hans & TognonGnnStandardzazne e taratura alna dTest NeuropsologSuppl. 8/ton .6 1987 The aln Journal of Neurologal Scnces - Zappalà G. Measso G., Cavarzeran F. Groletto F., Lebowz B., Pozzolo F., AmaduccL., MassarD., and Crook T. Agg and memory: correctns for age, sex and educatn fro three wely used memory tests - aln Journal Of Neurologal Scnces 1995;16: 177-184
Ben-Menachem E, Falter U. Effacy and toleraby of levetacetam 3000 mg/d patnts wh refractory partl seures: a multenter, double-bld, responder-selected study evaluatg monotherapy. European Levetacetam Study Group. Epeps. 2000 Oct;41(10):1276-83. do 10.1111/j.1528-1157.2000.tb04605.x.
Angehagen M, Margeanu DG, Ben-Menachem E, Ronnback L, Hansson E, Klgaard H. Levetacetam reduces caffee-duced Ca2+ transnts and epeptorm potentls hpocampal neurons. Neuroreport. 2003 Mar 3;14(3):471-5. do 10.1097/00001756-200303030-00035.
- Arroyo S, Crawford P. Safety profe of levetacetam. Epept Dorder 2003;5S1:S57-S63 - Ben-Menachem E, Edrh P, Van Vlyemen B, Sander JWAS, Schmt B. Evence for sustaed effacy of levetacetam as add-on epepsy therapy. Epepsy Res 2003;53:57-64 - Ben-Menachem E. Prelary effacy of levetacetam monoterapy. Epept Dorder 2003;5(Suppl 1):S51-S55 - Betts T, Yarrow H, Greenhl L, Barrett M. Clal expernce of marketed levetacetam an epepsy cl - a one year follow-up study. Seure 2003;12:140
Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis
Stephen LJ, Brod MJ. Epepsy elderly people. Lancet. 2000 Apr 22;355(9213):1441-6. do 10.1016/S0140-6736(00)02149-8.
zarD. The aln Gueles for stroke preventn. The Stroke Preventn and Educatnal Awareness Dfusn (SPREAD) Collaboratn. Neurol Sc 2000 Feb;21(1):5-12. do 10.1007/s100720070112. No abstract avaable.
Hauser WA, Annegers JF, Kurland LT. cence of epepsy and unprovoked seures Rochester, Mnesota: 1935-1984. Epeps. 1993 May-Jun;34(3):453-68. do 10.1111/j.1528-1157.1993.tb02586.x.
Blad CF, Alexandrov AV, Bellavance A, Bornste
Rhoney DH, Tps LB, Murry KR, Basham MC, Mhael DB, Copl WM. Antonvulsant prophylax and tg of seures after aneurysmal subarachno hemorrhage. Neurology. 2000 Jul 25;55(2):258-65. do 10.1212/wnl.55.2.258.
Olafsson E, Gudmundsson G, Hauser WA. Rk of epepsy long-term survors of surgery for aneurysmal subarachno hemorrhage: a populatn-based study eland. Epeps. 2000 Sep;41(9):1201-5. do 10.1111/j.1528-1157.2000.tb00326.x.
Berger AR, Lton RB, Lesser ML, Lantos G, Portenoy RK. Early seures followg tracerebral hemorrhage: platns for therapy. Neurology. 1988 Sep;38(9):1363-5. do 10.1212/wnl.38.9.1363.
Sung CY, Chu NS. Epept seures thrombot stroke. J Neurol. 1990 Jun;237(3):166-70. do 10.1007/BF00314589.
- Bnstl S., Wulfert E., Beck SG., Levetacetam (ucb L059) affects vro model of epepsy CA3 pyramal neurons whout alterg normal synapt transmsn. Naunyn Schmeberg Arch Pharmacol 1997: 356:611-618 - Bchoff U. And Schlobohm - Levetacetam Has No Effect On Voltage-Gated Potassm Currents Cultured Mouse Hpocampal Neurons. Epeps 43(Suppl. 8):88, 2002. - Bla L, Sheehy O, St-Hae JM, Bernr JP, Godfro P, Le Lorr J. Econom evaluatn of levetacetam as adjuncte therapy refractory epept patnts. Value Health 2002;5(6):509 - Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Dose-response effect of levetacetam 1000 and 2000 mg/day partl epepsy. Epepsy Research 2002;48:77-89
- Castlo et al., Cochrane Database Syst Rev 2000;(3):CD 002028 - Chadwk et al., Cochrane Database Syst Rev 2002;(2):CD 001416 - Chaewul et al., Cochrane Database Syst Rev 2001;(1):CD 001901 - Coupez R., Nolas JM, Browne TR Levetacetam, a new antpept agent: lack of vro and vo pharmacoket teractn wh phenyto patnt wh valpro ac. Epeps 2003;44:171-178 - Cramer JA, Arro C, Van Hammee G, Gauer LJ, Cereghno JJ. Effect of levetacetam on epepsy-related qualy of le. Yhe N132 study group. Epeps 2000;41:868-874 - Cramer JA, Van Hammee G, N132 study Group. Matenance of provement health-related qualy of le durg long-term treatment wh levetacetam. Epepsy Behav 2003;4:118-123
- Cramer J, De Rue K, Devsky O, Edrh P, Trble MR. A systemat revw of the behavral effects of levetacetam adults wh epepsy, cogne dorder or an anxty dorder durg clal trl. Epepsy Behav. 2003;4:124-132 - Cramer JA, Ben-Menachem E, Franch J. Revw of treatment optns for refractory epepsy: new medatns and vagal nerve stulatn. Epepsy Research 2001;47:17-25 - Cramer J.A., Lepp E., De Rue K., Eldrh P., Kramer G. - Toleraby of levetacetam elderly patnts wh CNS dorders - Epepsy Research 2003; 56:135-145 - Devsky O, Elger C. Effacy of levetacetam partl seure. Epept Dorder 2003;5(suppl 1):S27-S32
- FerrendellJ.A., French J., Lepp., Morrel M.J., Herbeuval A., Han J., Magnus L. - Use of levetacetam a populatn of patnts aged 65 years and older: a subset analys of the KEEPER trl - Epepsy & Behavr 2003; 4:702-709 - French J, Edrh P, Cramer JA. A systemat revw of safety profe of levetacetam: a new antpept drug. Epepsy Res 2001;47:77-90 - Fucks B, Glard M, Mhel P, Lynch B, Vertongen P, Leprce P, Klgaard H, Chatela P. - Localatn and photoaffy labellg of the levetrcetam ddg se rat bra and certa cell les Eur. J. Pharmacol 2003; 478, 11-19 - Glard M, Fucks B, Mhel P, Vertongen P, Massgham R, Chatela P Bdg characterth of [3H]ucb 30889 to levetacetam bdg ses rat bra Eur J Phamacol 2003; 478: 1-9
- Glno RA, Hrsemenzel R, Baltes E, et al fluence of new antpept drug (levetacetam ucb L057) on the pharmacokets and pharmacodynams of oral contraceptes Epeps 1996; 37 (Suppl.4):90 - Glauser TA, Pellock JM, Beb EM. Effacy and safety of levetacetam chdren wh partl seure: an open label trl. Epeps 2002;43:518-524 - Glauser TA, Dulac O. Prelary effacy of levetacetam chdren. Epept Dorder 2003;5(suppl 1):S45-S50 - Godfro P, Hart Y, Roberts R, Le Lorr J. Seure freedom patnts treated wh adjuncte levetacetam: econom evaluatn wh the NHS. Neurology 2003;60(S1):A433-A434 - Gower AJ, Hsch E, Boehrer A, et al. Effects of levetacetam, a novel antpept drug on convulsant acty two genet rat models of epepsy Epepsy Research 1995; 22: 207-13
- Gower AJ, Noyer M, Verloes R., et al. ucb L059, a novel antconvulsant drug: pharmacologal profle anals. Eur J Pharmacol. 1992; 222: 193-203 - Gu J., Lynch B. A., Anderson D., Klgaard H., Lu s., Elashoff M., Ebert U., Potschka H. - Loscher W. - The antpept drug levetacetam selectely mods kdlg-duced alteratns gene expressn the temporal lobe of rats. - European Journal of Neuroscnce Vol. 19, pp334-345, 2004 - Kastela-Nolst Trenè DGA, Hsch E. Levetacetam: prelary effacy generaled seure. Epept Dorder 2003;5(suppl 1):S39-S44 - Klgaard H, Matagne A, Gobert M, Mhel P Evence for a unue profe of levetacetam rodent models of seures and epepsy Eur. J. Pharmacology 1998; 353: 191-206
- Klgaard H, Pkanen A, Antpeptogenes, neuroprotectn, and dease modatn the treatment of epepsy: focus on levetacetam. Epept dorder 2003; 5:S9-S16 - Kraemer G, Eldrh P. Levetacetam Elderly patnts wh epepsy - The Ameran Eplepsy Socty and The Ameran Clal Neurophyslogy Socty - Jot Meetg November 30-December 5, 2001 - Krakow K, Walker M, Otoul C, Sander JWAS. Long-term contuatn of Levetacetam patnts wh refractory epepsy. Neurology 2001;56:1772-1774 - Krauss GL, Abou-khal B, Sheth SG. Effacy of levetacetam for treatment fo drug-restant generaled epepsy. Epeps 2001;42(suppl 7):181 - Krauss GL, Betts T, Abou-Khal B, Bergey G, Yarrow H, Mler A. Levetacetam treatment of path generaled epepsy. Seure 2003;12:617-620
- Lagae L, Buyse G, Deconck A, Ceulemans B. Effect of levetacetam refractory chdhood epepsy syndromes. Eur J Paedtr Neurol 2003;7:123-128 - Levy RH, Raguenau-Majless Baltes E Repeated admtratn of the novel antpept agent levetacetam does not alter dox pharmacokets and pharmacodynams healthy volunteers Epepsy Research 2001; 47: 55-63 - Loscher W, Honak D, Rundfeld C Antpeptogen effect of the novel antonvulsant levetacetam (ucb L059) the kdlg model of temporal lobe epepsy. - J. Pharmacologal Exp. Ther 1998; 284: 474-9 - Lukyanetz EA, Shkryl VM, Kostyuk PG Selecte blockade of
- Madeja M., Margeanu D.G., GorjA., Sp E., Boerrter P., Klgaard H., Et Al. Reductn Of Voltage-Operated Potassm Currents By Levetacetam: A Novel Antpept Mechanm Of Actn? - Neuropharmacology Oct-2003. 45(5):661-671. - Margeau D. G., Klgaard Henr Levetacetam - Mechanm of actn - Antpect drugs, 5th edn. Eded by R.H. Levy, R.H. Mattson, B.S. Meldrum, and E.Perucca. Phadelph: Lpcott Wlms & Wks, 2002 - Margeau DG, Klgaard H hn of neural hyperynchrony vro dferenttes levetacetam fro classal antpept drugs Pharmacol. Research 2000; 42(4): 281-285 - Marson AG, Hutton JL, Leach JP. Levetacetam, Oxcarbazepe, Remaceme and zoname for drug restant localatn-related epepsy: a systemat revw. Epepsy Res 2001;46:259-270
- Marson AG, Kad ZA, Hutton JL, Chadwk DW. The new antpept drugs: a systemat revw of the effacy and toleraby. Epeps 1997;38:859-880 - Morrell MJ, Lepp French J, FerrendellJ, Han J, Magnus L. The KEEPER trl: levetacetam adjuncte treatment of partl-onset seure an open-label communy-based study. Epepsy Res 2003;54:153-161 - Nspodzny Klgaard H, Margeau DG Desynchrong effect of levetacetam on epeptorm responses rat hpocampal sles Neuropharmaology Neuroreport 2003; vol14(9): 1273-1276 - Noyer M, Glard M, Magagne A., et al. The novel antpept drug levetacetam (ucb L059) appears o act v a spec bdg se CNS membranes. Eur J Pharmacol 1995 ; 286 : 137-146 - Patsalos PN Pharmacoket profe of levetacetam: toward eal characterts. Pharmacol. Ther 2000; 83: 77-85 - Patsalos PN The pharmacoket characterts of levetacetam. Method Fd. Exp. Cl Pharmacol. 2003; 25: 123-129
- Perucca E, Johannessen SThe eal pharmacoket properts of an antpept drug: how close does levetacetam come? Epept Dorder 2003; 5(suppl 1):S17-S26 - Perucca E. Pharmacokets. :Engel J Jr, Pedley TA Epepsy-A comprehense Textbook. New York: Raven Press 1997:1131-1153 - Radtke RA Pharmacokets of levetacetam Epeps 2001; 42(Suppl 4):24-7 - Raguenau-Majless Levy RH, Meyerhoff C Lack of effect of repeated admtratn of levetacetam on the pharmacodynams and pharmaket profe of warfar Epepsy Res 2001; 47: 55-63 - Ro JM, Hans G, Nguyen L, et al. The antpept drug levetacetam reverses the hn by negate alloster modulators of neuronal GABA - and Glyce-gated current. Br J Pharmacol 2002; 136:659-72 - Sadek AH, F A, French J. Levetacetam related behavural adverse events: a post-marketg study. Epeps, 2002;43S8:151
- Shorvon SD, Van Rckevorsel. A new antpept drug Levetacetam, a pyrrolone recently lensed as an antpept drug. J Neurol Neurosurg Psychtry 2002 ;72: 426-429 - Smh K, Betts T, Prchett L. Levetacetam, a promg optn for the treatment of juvene myoclon epepsy. Epeps 2000;41(suppl1):39 - Van Rckevorsel K. The " number needed to treat " wh levetacetam : comparon wh the other new antpept drugs. Seure 2001;10:235-236 - Welty TE, Gal BE, Fker DM, Prera MD. Levetacetam: a dferent approach to the pharmacotherapy of epepsy. The Annals of Pharmacotherapy 2002;36:296-304 - Zona C, Nspodzny MarchettC, et al. Levetacetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seure 2001; 10: 279-86
- Groletto Francesco, Zappalà Gseppe, Anderson Dallas W., Lebowz Barry D. Norms for the M-Mental State Examatn a Healthy populatn. Neurology 1999;53:315-320 - Measso G., Zappalà G., Cavarzeran F, Crook TH, RomanL, Pozzolo FJ, Groletto F., AmaduccLA, Lebowz BD. Raven's colored progresse matres: a normate study of a random sample of healthy adults. Acta Neurol. Scandava 1993:88:70-74 - Spnler Hans & TognonGnnStandardzazne e taratura alna dTest NeuropsologSuppl. 8/to
Ben-Menachem E, Falter U. Effacy and toleraby of levetacetam 3000 mg/d patnts wh refractory partl seures: a multenter, double-bld, responder-selected study evaluatg monotherapy. European Levetacetam Study Group. Epeps. 2000 Oct;41(10):1276-83. do 10.1111/j.1528-1157.2000.tb04605.x.
Angehagen M, Margeanu DG, Ben-Menachem E, Ronnback L, Hansson E, Klgaard H. Levetacetam reduces caffee-duced Ca2+ transnts and epeptorm potentls hpocampal neurons. Neuroreport. 2003 Mar 3;14(3):471-5. do 10.1097/00001756-200303030-00035.
- Arroyo S, Crawford P. Safety profe of levetacetam. Epept Dorder 2003;5S1:S57-S63 - Ben-Menachem E, Edrh P, Van Vlyemen B, Sander JWAS, Schmt B. Evence for sustaed effacy of levetacetam as add-on epepsy therapy. Epepsy Res 2003;53:57-64 - Ben-Menachem E. Prelary effacy of levetacetam monoterapy. Epept Dorder 2003;5(Suppl 1):S51-S55 - Betts T, Yarrow H, Greenhl L, Barrett M. Clal expernce of marketed levetacetam an epepsy cl - a one year follow-up study. Seure 2003;12:140
Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis
검색 결과 제한하기
제한된 항목
[검색어] Margineau, N.
발행연도 제한
-
학술DB(Database Provider)
자료유형(Source Type)
주제어
언어